ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,856
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Brigatinib versus crizotinib in ALKpositive non–small-cell lung cancer
Author(s):
DR Camidge
,
HR Kim
,
M-J Ahn
Publication date:
2018
Journal:
N Engl J Med
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
open (via page says license)
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Inflamed lung in vitro co-culture models
Author and article information
Journal
DOI::
10.1200/JCO.20.00505
PubMed ID::
30280657
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,856
Brigatinib outperforms crizotinib as first-line therapy
Authors:
Breakthrough Therapy Designation, Case study Brigatinib
Authors:
Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials
Authors:
SN Gettinger
,
D. Kim
,
M Tiseo
See all similar
Cited by
1
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective
Authors:
Holly Cranmer
,
Isabella Kearns
,
Melanie Young
…
See all cited by